×
About 16,063,593 results

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 31st, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

Locoregional Treatment of Intact Primary Tumor Does Not Improve Survival, HRQoL in Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200210/full/

May 31st, 2020 - Early initiation of locoregional treatment (LRT) of an intact primary tumor (IPT) in women with de novo stage IV metastatic breast cancer does not appear to prolong survival or improve health-related quality of life (HRQoL) compared with systemic therapy alone, according to a new study (Abstract LBA2). Seema A. Khan, MD, of the Northwestern Memorial Hospital, presented these findings during the...

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/baseline-and-posttreatment-ctdna-positivity-linked-to-poor-prognosis-rpfs-in-mcrpc

May 31st, 2020 - Baseline and posttreatment circulating tumor DNA (ctDNA) positivity was associated with worse radiologic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to a correlative analysis from the randomized phase 2 A.MARTIN trial presented at the 2020 Virtual Scientific Meeting.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 31st, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy regardless of prior therapy, according to data from a pooled analysis of patients treated on the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C20...

Cabozantinib Plus Atezolizumab Shows Promise in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-plus-atezolizumab-shows-promise-in-mcrpc

May 31st, 2020 - The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features, according to findings from the phase 1b COSMIC-021 trial presented during the 2020 ASCO Virtual Scientific Program.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC
https://www.onclive.com/conference-coverage/asco-2020/darolutamide-improves-os-delays-onset-of-cancer-related-morbidity-and-subsequent-chemo-in-nonmetastatic-crpc

May 31st, 2020 - Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results of a preplanned final overall survival (OS) analysis of the phase III ARAMIS trial, which were presented during the 2020 ASCO Virtual Scientific Program.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/asco-2020/pyrotinib-combo-improves-pfs-in-her2-mbc

May 31st, 2020 - Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/robust-data-and-multivariate-analyses-support-cabazitaxel-as-a-standard-of-care-in-mcrpc

May 31st, 2020 - The use of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) may continue as a standard of care in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, based on results of a poster presented during the 2020 American Society of Clinical Oncology Virt...

OncLive News Network On Location: ASCO 2020 Day 2
https://www.onclive.com/inside-oncology/asco-2020-news/onclive-news-network-on-location-asco-2020-day-2

May 31st, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.

Clinically Meaningful Activity Observed With Combination Cabozantinib and Atezolizumab in mCRPC
https://www.targetedonc.com/view/clinically-meaningful-activity-observed-with-combination-cabozantinib-and-atezolizumab-in-mcrpc

May 31st, 2020 - According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features.

ctDNA Positivity Correlates With Poor Survival Outcomes in mCRPC
https://www.targetedonc.com/view/ctdna-positivity-correlates-with-poor-survival-outcomes-in-mcrpc

May 31st, 2020 - Circulating tumor DNA (ctDNA) showing positivity in patients with metastatic castration-resistant prostate cancer (mCRPC) at baseline and posttreatment in the randomized phase 2 A.MARTIN trial was associated with worse radiologic progression-free survival (rPFS), according to a correlative analysis presented at the 2020 Virtual Scientific Meeting.

Darolutamide Demonstrates Improved OS Over Placebo in Phase 3 ARAMIS Trial for Nonmetastatic CRPC
https://www.targetedonc.com/view/darolutamide-demonstrates-improved-os-over-placebo-in-phase-3-aramis-trial-for-nonmetastatic

May 31st, 2020 - Patients with nonmetastatic castration-resistant prostate cancer (CRPC) receiving darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival (OS) analysis presented during the 2020 ASCO Virtual Scientific Program.

DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer
https://www.targetedonc.com/view/dfs-improvement-not-significant-with-anti-pd-l1-in-muscle-invasive-urothelial-cancer

May 31st, 2020 - Adjuvant treatment with anti–PD-L1 therapy demonstrated a numerically increased but not statistically significant improvement in disease-free survival (DFS) compared with observation in patients with muscle-invasive urothelial carcinoma (MIUC) in a primary analysis presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program. DFS was the primary end point of the IMvigo...

Investigation of Tepotinib Shows Durable Benefit in NSCLC With a METex14 Skipping Mutation May 31, 2020
https://www.targetedonc.com/view/investigation-of-tepotinib-shows-durable-benefit-in-nsclc-with-a-metex14-skipping-mutation

May 31st, 2020 - Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a MET exon 14 (METex14) skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial (NCT02864992) presented during the at the 2020 Virtual Scientific Meeting and pu...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 31st, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review
https://www.targetedonc.com/view/pralsetinib-demonstrates-significant-findings-in-ret-solid-tumors-as-fda-grants-priority-review

May 31st, 2020 - Pralsetinib (BLU-667) demonstrated significant efficacy across various advanced solid tumor types harboring RET alterations, including in patients with difficult-to-treat cancers, according to findings from a subgroup of the ongoing phase 1/2 ARROW trial (NCT03037385) presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
https://www.targetedonc.com/view/statistical-analyses-confirm-benefit-of-cabazitaxel-over-abiraterone-or-enzalutamide-in-mcrpc

May 31st, 2020 - Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) as a standard treatment in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, accor...

Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
https://www.targetedonc.com/view/updated-data-displays-better-os-with-use-of-alectinib-over-crizotinib-in-alk-nsclc

May 31st, 2020 - Patients with ALK-positive non–small cell lung cancer (NSCLC) showed clinically meaningful improvement in overall survival (OS) when receiving alectinib (Alecensa), a highly selective second-generation TKI, versus those treated with crizotinib (Xalkori), according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.

5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma
https://www.onclive.com/conference-coverage/asco-2020/5year-followup-of-combiad-confirms-longterm-rfs-benefit-with-dabrafenib-and-trametinib

May 30th, 2020 - Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with resected, stage III BRAF V600E/K-mutant melanoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors
https://www.onclive.com/conference-coverage/asco-2020/dr-van-tine-on-next-steps-with-adpa2m4-in-advanced-solid-tumors

May 30th, 2020 - Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.